Objective-High baseline YKL-40 is associated with later development of ischemic stroke, but not with myocardial infarction. Whether high YKL-40 levels are associated with increased risk of venous thromboembolism is presently unknown. We tested the hypothesis that observationally and genetically high YKL-40 is associated with increased risk of venous thromboembolism in the general population. Approach and Results-Cohort and Mendelian randomization studies in 96 110 individuals from the Danish general population, with measured plasma levels of YKL-40 (N=21 647) and CHI3L1 rs4950928 genotype (N=94 579). From 1977 to 2013, 1489 individuals developed pulmonary embolism, 2647 developed deep vein thrombosis, and 3750 developed venous thromboembolism (pulmonary embolism and deep vein thrombosis). For the 91% to 100% versus 0% to 33% YKL-40 percentile category, the multifactorially adjusted hazard ratio was 2.38 (95% confidence interval, 1.25-4.55) for pulmonary embolism, 1.98 (1.09-3.59) for deep vein thrombosis, and 2.13 (1.35-3.35) for venous thromboembolism. Compared with rs4950928 GG homozygosity, presence of C-allele was associated with a doubling (CG) or tripling (CC) in YKL-40 levels, but not with risk of venous thromboembolism. A doubling in YKL-40 was associated with a multifactorially adjusted observational hazard ratio for pulmonary embolism of 1.17 (1.00-1.38) and a genetic odds ratio of 0.97 (0.76-1.23). Corresponding risk estimates were 1.28 (1.12-1.47) observationally and 1.11 (0.91-1.35) genetically for deep vein thrombosis and 1.23 (1.10-1.38) observationally and 1.08 (0.92-1.27) genetically for venous thromboembolism. Conclusions-High YKL-40 levels were associated with a 2-fold increased risk of venous thromboembolism, but the association was not causal. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
Y KL-40 is a 40-kDa plasma glycoprotein. It comprises 383 amino acids, where the 3 N-terminal amino acids are Y (tyrosine), K (lysine), and L (leucine). It is produced by lipid-laden macrophages inside the vessel wall 1 and is high in patients with ischemic cardiovascular disease. 2 In prospective cohort studies, high baseline plasma YKL-40 was associated with later development of ischemic stroke, but not with myocardial infarction. [3] [4] [5] [6] Whether high plasma YKL-40 is associated with increased risk of venous thromboembolism has never been studied before.
The aim of this study was to test the hypothesis that observationally and genetically high YKL-40 is associated with increased risk of venous thromboembolism. For this purpose, we performed cohort and Mendelian randomization studies in 96 110 individuals from the Danish general population. The Mendelian randomization method uses genetic variants associated with lifelong high plasma YKL-40 levels that are largely unconfounded and not prone to reverse causation. 7, 8 Thus, the method mimics a controlled double-blind randomized trial, but it uses genetic variants rather than a drug and placebo, and like a blinded trial, it allows inference about causality. rs4950928, a single nucleotide polymorphism (SNP) in the proximal promoter of CHI3L1, explains 14% of the variation in plasma YKL-40 levels in the Danish general population. 6 This promoter SNP is functional because the major C-allele binds MYC/MAX transcriptional factors with higher affinity than the G-allele. 9 The binding of transcriptional factors increases CHI3L1 transcription 10 and, consequently, elevates YKL-40 levels. [11] [12] [13] First, in the cohort study, we examined the association of high YKL-40 levels (N=21 647, participants followed from 
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Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
We performed cohort and Mendelian randomization studies in 96 110 individuals from the Danish general population, with measured plasma levels of YKL-40 (N=21 647) and CHI3L1 rs4950928 genotype (N=94 579). A flow diagram of the studies is shown in Figure I in the online-only Data Supplement.
Results
The combined studies included 96 110 individuals from the Danish general population, of which 21 647 had plasma YKL-40 measured, and 94 579 were genotyped for rs4950928; we only show combined results because the results for the 2 studies separately were similar. From 1977 to 2013, 1489 individuals developed pulmonary embolism, 2647 developed deep vein thrombosis, and 3750 developed venous thromboembolism ( genotype was associated with none and, therefore, can be used as a largely unconfounded instrument to study the importance of lifelong high plasma YKL-40 levels not prone to reverse causation.
Plasma YKL-40 Distribution and Association With Age
Distribution of plasma YKL-40 levels in the general population is shown in Figure II in the online-only Data Supplement. Because plasma YKL-40 increases with increasing age, YKL-40 percentile categories allowed for age differences (Figure 1 ).
Plasma YKL-40 and Covariates Used in Multifactorially Adjusted Models: Potential Interactions
We cannot completely exclude interactions between a doubling in plasma YKL-40 levels and covariates, such as sex, age, cumulative smoking, hypertension, any cancer, total cholesterol, LDL cholesterol, and study population on risk of pulmonary embolism, deep vein thrombosis, and venous thromboembolism ( Table III in the online-only Data Supplement). However, these potential interactions were not observed consistently across the 3 end points, and none of the interactions remained statistically significant after correction for multiple comparisons (Bonferroni P<0.05/60=0.0008). Furthermore, when analyses were stratified by covariates categorized into 2 categories, the risk estimates of venous thrombembolism by a doubling in plasma YKL-40 levels were similar across all categories (data not shown).
Plasma YKL-40 and Venous Thromboembolism: Cohort Study
Risk of venous thromboembolism increased with increasing plasma YKL-40 percentile category (Figure 2 ). For the 91% to 100% versus 0% to 33% YKL-40 percentile category, the multifactorially adjusted hazard ratio was 2.38 (95% confidence interval, 1.25-4.55) for pulmonary embolism, 1.98 (1.09-3.59) for deep vein thrombosis, and 2.13 (1.35-3.35) for venous thromboembolism.
Risk estimates were similar for shorter follow-up time, but with wider confidence intervals because of fewer events ( Table IV in Figure 1 ). We also used age as time scale in Cox regression (for further details, see Materials and Methods in the onlineonly Data Supplement). Four hundred and one individuals with venous thrombolism events before blood sampling were excluded from analyses of the total of 21 647 participants with measured plasma YKL-40 levels. The multifactorially adjusted model included automatical adjustments for age and sex and adjustments for smoking, alcohol consumption, body mass index, diabetes mellitus, hypertension, any cancer, physical activity, postmenopausal status, oral contraceptives use, hormone replacement therapy, lipid-lowering treatment, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, and study population. P values are for Cuzick's nonparametric test for trend. 
CHI3L1 rs4950928 Genotype, Plasma YKL-40, and Venous Thromboembolism: Mendelian Randomization Study
There was a doubling (107% increase) in mean of plasma YKL-40 levels from GG (4.4% of individuals) to CG (32.9% of individuals) genotype and a tripling (211% increase) in levels from GG to CC (62.7% of individuals) genotype (Figure 3 ; P value for trend <1×10 −300 ); genotype explained 14% of the variation in plasma YKL-40 levels, and the F statistic was 1690, indicating that rs4950928 is a strong instrument to examine the effect of lifelong elevated plasma YKL-40 levels.
Mean for plasma YKL-40 was 31 μg/L for individuals with the GG genotype, 63 μg for the CG genotype, and 95 μg/L for the CC genotype. Similarly, geometric mean for plasma YKL-40 was 24, 48, and 71 μg/L for GG, CG, and CC genotypes, respectivelly. CHI3L1 rs4950928 genotype was not associated with risk of venous thromboembolism (Figure 4 ).
Observationally Versus Genetically Elevated Plasma YKL-40 Levels and Venous Thromboembolism: Cohort and Mendelian Randomization Studies
A doubling in YKL-40 was associated with a multifactorially adjusted observational hazard ratio for pulmonary embolism of 1.17 (1.00-1.38) and a genetic odds ratio of 0.97 (0.76-1.23; Figure 5 ). Corresponding risk estimates were 1.28 (1.12-1.47) observationally and 1.11 (0.91-1.35) genetically for deep vein thrombosis and 1.23 (1.10-1.38) observationally and 1.08 (0.92-1.27) genetically for venous thromboembolism. Hazard ratios (HR) of venous thromboembolism according to CHI3L1 rs4950928 genotype. The rare homozygote (GG) is the reference group. Individuals with events before blood sampling were not excluded from analyses of the total of 94 579 genotyped participants because genotype precedes events.The multifactorially adjusted model included adjustments for age, sex, smoking, alcohol consumption, body mass index, diabetes mellitus, hypertension, any cancer, physical activity, postmenopausal status, oral contraceptives use, hormone replacement therapy, lipid-lowering treatment, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, and study population.
Plasma YKL-40 and Risk Prediction of Venous Thromboembolism
At the cut off value set at 95% percentile, plasma YKL-40 performed poorly as a marker of future risk of venous thromboembolism. Sensitivity was 7.1%, specificity 95.1%, positive predictive value 5.1%, and negative predictive value 96.5%. Area under the reciever operating characteristics curve was 0.51.
The absolute risk of venous thromboembolism as a function of age, body mass index, smoking, and plasma YKL-40 percentile categories is shown in Figures III-V in the onlineonly Data Supplement. For every plasma YKL-40 percentile category, the risk was higher in individuals who were older, were smokers, and had higher body mass index.The risk increased stepwise with increasing plasma YKL-40 categories.
Discussion
Studying 96 110 individuals from the general population, we found that high plasma YKL-40 levels were associated with more than a 2-fold increased risk of venous thromboembolism, but the association was not causal. These are novel findings because the association between YKL-40 and venous thromboembolism has never been investigated previously.
Mechanistically, these findings may be explained by another common factor that causes both high plasma YKL-40 levels and venous thromboembolism. Another explanation could be that elevated plasma YKL-40 at time of blood sampling might be a early marker of small and preclinical venous thromboembolism, which is associated with increased risk of later development of symptomatic venous thromboembolism. Also, as plasma YKL-40 levels are high in cancer patients, 14, 15 elevated plasma YKL-40 at time of blood sampling could be a marker for participants with cancer, known or unknown, who are in turn more likely to have later venous thromboembolism than participants without cancer. Importantly, we did adjust for diagnosed cancer. However, all the proposed mechanisms are highly speculative because the study was not designed to answer these questions.
Plasma YKL-40 performed poorly as a marker of future risk of venous thromboembolism, with low sensitivity and positive predictive value. This probably precludes the use of plasma YKL-40 in risk assesment and screening in the general population.
Because plasma YKL-40 is a marker of inflammation, 16 it is tempting to speculate that the underlying inflammation might cause both high plasma YKL-40 levels and venous thromboembolism.
Indeed, risk of venous thromboembolism with increasing plasma YKL-40 percentile category did not change by the length of follow-up time. This suggests that a fixed underlying factor determines the association with venous thromboembolism.
Moreover, we showed that obesity, smoking, hypertension, diabetes mellitus, and dyslipidemia, all of which are inflammatory diseases, were all associated with high plasma YKL-40 levels, as well as increased risk of venous thromboembolism. However, we did adjust analyses for low-grade inflammation detected as slightly elevated levels of C-reactive protein.
Limitations of the present study include survival bias. A fraction of venous thromboembolic events are lethal, and we cannot completely exclude underrepresentation of individuals with lethal venous thromboembolic events in our sample of the general population. Another potentially underrepresented group are individuals being sick because of venous thromboembolism (selective nonresponse). Both would, however, likely bias the results toward the null hypothesis and, therefore, are unlikely to explain our findings. Yet another potential limitation is that we used register-based and not individually validated diagnoses of venous thromboembolism. However, any misclassification of diagnoses in the present studies is likely to be random and, thus, would tend to underestimate, rather than overestimate, the true association. Unfortunately, D-dimer was not measured in this population, and we could not perform any correlation tests between YKL-40 and D-dimer. Further potential limitations are linkage diseqilibrium and Figure 5 . Observational hazard ratios (HR) and genetic odds ratios (OR) of venous thromboembolism for a doubling in plasma YKL-40 levels. The multifactorially adjusted model included adjustments for age, sex, smoking, alcohol consumption, body mass index, diabetes mellitus, hypertension, any cancer, physical activity, postmenopausal status, oral contraceptives use, hormone replacement therapy, lipid-lowering treatment, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, and study population. The observational model is based on Cox regression, and risk estimates are expressed as hazard ratios. The genetic model is based on a control function estimator with a logistic regression at second stage, and risk estimates are expressed as odds ratios. P values are from z-scores in regression analyses, testing whether risk estimates significantly differ from 1. We did not perform statistical analyses between observational hazard ratios and genetic odds ratios. pleiotropy. However, rs4950928 is a functional promoter SNP influencing plasma YKL-40 levels without influencing protein stucture. Our negative results regarding rs4950928 are likely accurate because the distribution of genotypes did not deviate from Hardy-Weinberg equilibrium and because the instrument used explained as much as 14% of plasma YKL-40 levels and had an extremely high F value of 1690. Furthermore, CHI3L1 SNPs rs1538372, rs2071579, rs880633, and rs946259 were only associated with plasma YKL-40 levels through their modest to strong linkage disequilibrium with rs4950928. 6 Pleiotropy is often impossible to refute completely, but because CHI3L1 rs4950928 is a promoter SNP and not associated with venous thromboembolism, it is unlikely. Finally, as we only studied white individuals of Danish descent, our results are not necessarily directly applicable to other ethnic groups; however, we are not aware of data to suggest that the present results should not be applicable to most ethnic groups.
In conclusion, in this large prospective study of subjects from the general population, we found that high plasma YKL-40 levels were associated with more than a 2-fold increased risk of venous thromboembolism, but the association was not causal.
